Cargando…
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision mak...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043164/ https://www.ncbi.nlm.nih.gov/pubmed/36998457 http://dx.doi.org/10.3389/fonc.2023.1152467 |
_version_ | 1784913082253836288 |
---|---|
author | Assanto, Giovanni Manfredi Del Giudice, Ilaria Della Starza, Irene Soscia, Roberta Cavalli, Marzia Cola, Mattia Bellomarino, Vittorio Di Trani, Mariangela Guarini, Anna Foà, Robin |
author_facet | Assanto, Giovanni Manfredi Del Giudice, Ilaria Della Starza, Irene Soscia, Roberta Cavalli, Marzia Cola, Mattia Bellomarino, Vittorio Di Trani, Mariangela Guarini, Anna Foà, Robin |
author_sort | Assanto, Giovanni Manfredi |
collection | PubMed |
description | Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision making tool. Several molecular techniques are employed to monitor MRD, from conventional real-time quantitative polymerase chain reaction (RQ-PCR) to next generation sequencing and digital droplet PCR (ddPCR), in different tissues or compartments through the detection of fusion genes, immunoglobulin and T-cell receptor gene rearrangements or disease-specific mutations. RQ-PCR is still the gold standard for MRD analysis despite some limitations. ddPCR, considered the third-generation PCR, yields a direct, absolute, and accurate detection and quantification of low-abundance nucleic acids. In the setting of MRD monitoring it carries the major advantage of not requiring a reference standard curve built with the diagnostic sample dilution and of allowing to reduce the number of samples below the quantitative range. At present, the broad use of ddPCR to monitor MRD in the clinical practice is limited by the lack of international guidelines. Its application within clinical trials is nonetheless progressively growing both in acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia and non-Hodgkin lymphomas. The aim of this review is to summarize the accumulating data on the use of ddPCR for MRD monitoring in chronic lymphoid malignancies and to highlight how this new technique is likely to enter into the clinical practice. |
format | Online Article Text |
id | pubmed-10043164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100431642023-03-29 Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? Assanto, Giovanni Manfredi Del Giudice, Ilaria Della Starza, Irene Soscia, Roberta Cavalli, Marzia Cola, Mattia Bellomarino, Vittorio Di Trani, Mariangela Guarini, Anna Foà, Robin Front Oncol Oncology Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision making tool. Several molecular techniques are employed to monitor MRD, from conventional real-time quantitative polymerase chain reaction (RQ-PCR) to next generation sequencing and digital droplet PCR (ddPCR), in different tissues or compartments through the detection of fusion genes, immunoglobulin and T-cell receptor gene rearrangements or disease-specific mutations. RQ-PCR is still the gold standard for MRD analysis despite some limitations. ddPCR, considered the third-generation PCR, yields a direct, absolute, and accurate detection and quantification of low-abundance nucleic acids. In the setting of MRD monitoring it carries the major advantage of not requiring a reference standard curve built with the diagnostic sample dilution and of allowing to reduce the number of samples below the quantitative range. At present, the broad use of ddPCR to monitor MRD in the clinical practice is limited by the lack of international guidelines. Its application within clinical trials is nonetheless progressively growing both in acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia and non-Hodgkin lymphomas. The aim of this review is to summarize the accumulating data on the use of ddPCR for MRD monitoring in chronic lymphoid malignancies and to highlight how this new technique is likely to enter into the clinical practice. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043164/ /pubmed/36998457 http://dx.doi.org/10.3389/fonc.2023.1152467 Text en Copyright © 2023 Assanto, Del Giudice, Della Starza, Soscia, Cavalli, Cola, Bellomarino, Di Trani, Guarini and Foà https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Assanto, Giovanni Manfredi Del Giudice, Ilaria Della Starza, Irene Soscia, Roberta Cavalli, Marzia Cola, Mattia Bellomarino, Vittorio Di Trani, Mariangela Guarini, Anna Foà, Robin Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
title | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
title_full | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
title_fullStr | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
title_full_unstemmed | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
title_short | Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? |
title_sort | research topic: measurable residual disease in hematologic malignancies. can digital droplet pcr improve measurable residual disease monitoring in chronic lymphoid malignancies? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043164/ https://www.ncbi.nlm.nih.gov/pubmed/36998457 http://dx.doi.org/10.3389/fonc.2023.1152467 |
work_keys_str_mv | AT assantogiovannimanfredi researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT delgiudiceilaria researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT dellastarzairene researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT sosciaroberta researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT cavallimarzia researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT colamattia researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT bellomarinovittorio researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT ditranimariangela researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT guarinianna researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies AT foarobin researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies |